



Synartro completes dosing of first cohort in clinical study of SYN321

Synartro AB announces that it has completed the treatment of the first out of four participant cohorts in its phase 1/2a clinical study of SYN321. The second cohort is expected to be dosed within the coming weeks.

Synartro's investigational drug SYN321 is a novel joint injection treatment targeting symptoms of knee osteoarthritis. The purpose of the ongoing phase 1/2a study is to evaluate safety and tolerability, as well as to obtain exploratory efficacy data. The first study participant was dosed on September 1st, 2025 and the study is expected to be completed in the spring of 2026. It is conducted together with partner CTC at Uppsala University Hospital in Sweden.

A total of seven participants were dosed in the first cohort and the study's safety review committee has now given the green light to proceed with the next cohort. The dosing of the second cohort is expected to commence in the final week of September.

'Entering the clinical stage is the most significant milestone so far for Synartro and it means a major step forward in our quest to provide a better option for the hundreds of millions of people suffering from OA related pain. Our Chief Development Officer Antonio Bermejo Gómez has made a tremendous effort together with the team to get us here. We are also extremely grateful for the expertise, trust and loyalty of our advisors, suppliers and investors. The study is progressing according to plan and the high interest to participate is very encouraging,' says Magnus Hurst, CFO & acting CEO.

For further information, please contact:

Magnus Hurst, CFO & acting CEO. Tel: +46 (0) 760 27 44 27. E-mail: magnus.hurst@synartro.com

About Synartro AB

Synartro is a Swedish life science company developing local injection treatments that provide superior and sustained efficacy without systemic side-effects. This is achieved by combining our proprietary slow-release technology with existing proven drugs. Our lead candidate drug SYN321 is a novel treatment of symptomatic osteoarthritis (OA). A disease that leaves hundreds of millions of patients without adequate pain relief.

In addition to the founders, major shareholders include life science investment company Linc AB.